Rafael Holdings to Present at Sidoti Fall 2018 Investor Conference
NEWARK, N.J., Sept. 21, 2018 /PRNewswire/ -- Rafael Holdings, Inc. (NYSE American: RFL) today announced that its Chief Financial Officer, David Polinsky, will present an overview of the Company's business and strategy at the Sidoti & Company Fall 2018 Investor Conference. The presentation will begin at 1:30 PM Eastern on Thursday, September 27, 2018.
Presentation slides will be available for download in the investor relations section of the Rafael Holdings website, www.rafaelholdings.com.
The Sidoti & Co. conference will be held at The Grand Hyatt in New York, NY. Mr. Polinsky will be meeting with conference attendees throughout the day. Investors wishing to schedule a meeting should email email@example.com.
All statements above that are not purely about historical facts, including, but not limited to, those in which we use the words "believe," "anticipate," "expect," "plan," "intend," "estimate," "target" and similar expressions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. While these forward-looking statements represent our current judgment of what may happen in the future, actual results may differ materially from the results expressed or implied by these statements due to numerous important factors. Our filings with the SEC provide detailed information on such statements and risks, and should be consulted along with this release. To the extent permitted under applicable law, Rafael Holdings, Inc. assumes no obligation to update any forward-looking statements.
About Rafael Holdings, Inc.:
Rafael Holdings holds commercial real estate assets and interests in two clinical stage pharmaceutical companies. The real estate holdings consist of properties in Newark and Piscataway, New Jersey and Jerusalem, Israel. The pharmaceutical holdings consist of interests in Rafael Pharmaceuticals, Inc. and a majority stake in Lipomedix Pharmaceuticals Ltd. Both are focused on development and commercialization of drugs in the oncology space. For more information, visit www.rafaelholdings.com